u/Glad-River7299

The author claims IOVA is a severely undervalued FDA-approved biotech whose product is ramping and whose shares have been shorted into oblivion, with about 30% short interest and limited available shares to short. They expect near-term catalysts in late February/early March, including revenue results and product-ramp updates, to force short covering and drive the stock higher from around $2.69 after recent liquidations and sharp volume spikes. The author states they are long calls.

The author argues OPFI's trailing PE of 144x is misleading because the company has been in a heavy growth-investment phase, and if Q4 results come in as advised the trailing PE resets to roughly 17-18x with forward PE around 5-6x. They claim revenues are rising while costs stabilize or decline, and that a new AI underwriting model is producing better results validated by bank partnerships. Institutions have been accumulating while financials are skewed, and the author expects a re-rating once Q4 results are released. The author acknowledges sub-prime lending is seen as taboo as the main concern.